دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
Alberto Ortiz, Christoph Wanner, Ron Gansevoort, the ERA Council
doi : 10.1093/ckj/sfac199
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 403–407
The European Society of Cardiology 2021 guideline on cardiovascular (CV) disease (CVD) prevention in clinical practice has major implications for both CV risk screening and kidney health of interest to primary care physicians, cardiologists, nephrol-ogists, and other professionals involved in CVD prevention.
MicroRNAs: emerging biomarkers and therapeutic targets of bone fragility in chronic kidney disease
Dieter Smout, Amaryllis H Van Craenenbroeck, Hanne Skou Jørgensen, Pieter Evenepoel
doi : 10.1093/ckj/sfac219
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 408–421,
Bone fragility is highly prevalent, yet underdiagnosed in patients with chronic kidney disease. Incomplete understanding of the pathophysiology and limitations of current diagnostics contribute to therapeutic hesitation, if not nihilism.
Home dialysis in older adults: challenges and solutions
Henry H L Wu, Ajay P Dhaygude, Sandip Mitra, Karthik K Tennankore
doi : 10.1093/ckj/sfac220
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 422–431
There is a rising demand for dialysis in the older population given the increased numbers of older adults living with chronic kidney disease (CKD) progressing to kidney failure. Home dialysis, i.e.
PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations
Marta Casal Moura, Cynthia S Crowson, Ulrich Specks, Kenneth J Warrington, Ladan Zand, Sanjeev Sethi, Fernando C Fervenza
doi : 10.1093/ckj/sfac221
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 432–436
The risk of progression to end-stage kidney disease (ESKD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and glomerulonephritis (AAV-GN) remains high.
Unmet needs in clinical trials in CKD: questions we have not answered and answers we have not questioned
Adeera Levin, Megan Borkum
doi : 10.1093/ckj/sfac226
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 437–441
Many advances have been made in the field of nephrology over the last decade. These include an increasing focus on patient-centred involvement in trials, exploration of innovative trial designs and methodology, the growth of personalized medicine and, most importantly, novel therapeutic agents that are disease-modifying for large groups of patients with and without diabetes and chronic kidney disease.
The Many Faces of NELL1 MN
Sanjeev Sethi
doi : 10.1093/ckj/sfac237
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 442–446
Neural tissue encoding protein with EGF-like repeats (NELL1) is a recently discovered target antigen in membranous nephropathy (MN).
Donor liquid biopsy and outcomes in kidney transplantation
Miriam Anfaiha-Sanchez, Emilio Rodrigo Calabia, Alberto Ortiz, Marta Martin-Lorenzo, Gloria Alvarez-Llamas
doi : 10.1093/ckj/sfac227
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 447–455
Kidney transplantation is the treatment of choice for patients with kidney failure. Priority on the waiting list and optimal donor–recipient matching are guided by mathematical scores, clinical variables and macroscopic observation of the donated organ
Management of fracture risk in CKD—traditional and novel approaches
Mathias Haarhaus, Louise Aaltonen, Daniel Cejka, Mario Cozzolino, Renate T de Jong, Patrick D'Haese, Pieter Evenepoel, Marie-Hélène Lafage-Proust, Sandro Mazzaferro, Eugene McCloskey, Syazrah Salam, Hanne Skou Jørgensen, Marc Vervloet
doi : 10.1093/ckj/sfac230
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 456–472
The coexistence of osteoporosis and chronic kidney disease (CKD) is an evolving healthcare challenge in the face of increasingly aging populations. Globally, accelerating fracture incidence causes disability, impaired quality of life and increased mortality.
Kidney Donor Profile Index and allograft outcomes: interactive effects of estimated post-transplant survival score and ischaemic time
Janelle Prunster, Germaine Wong, Nicholas Larkins, Kate Wyburn, Ross Francis, William R Mulley, Esther Ooi, Helen Pilmore, Christopher E Davies, Wai H Lim
doi : 10.1093/ckj/sfac243
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 473–483
The Kidney Donor Profile Index (KDPI) is routinely reported by the donation agencies in Australia. We determined the association between KDPI and short-term allograft loss and assessed if this association was modified by the estimated post-transplant survival (EPTS) score and total ischaemic time.
Kidney function before and after acute kidney injury: a nationwide population-based cohort study
Simon Kok Jensen, Uffe Heide-Jørgensen, Søren Viborg Vestergaard, Henrik Gammelager, Henrik Birn, Dorothea Nitsch, Christian Fynbo Christiansen
doi : 10.1093/ckj/sfac247
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 484–493
Acute kidney injury (AKI) is a common and serious condition defined by a rapid decline in kidney function. Data on changes in long-term kidney function following AKI are sparse and conflicting.
Performance of real-time PCR in suspected haemodialysis catheter-related bloodstream infection: a proof-of-concept study
Mathieu Acquier, Arnaud Zabala, Valérie de Précigout, Yahsou Delmas, Véronique Dubois, Renaud de la Faille, Sébastien Rubin, Christian Combe, Fatima M'Zali, Hannah Kaminski
doi : 10.1093/ckj/sfac242
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 494–500
Catheter-related bloodstream infections (CRBIs) remain a major cause of mortality in haemodialysis (HD) patients with central venous catheters (CVCs), especially because of the non-specific symptomatology and the delay in microbiological diagnosis with possible use of non-optimal empiric antibiotics.
Management of anaemia in French dialysis patients: results from a large epidemiological retrospective study
Philippe Zaoui, Cecile Courivaud, Guy Rostoker, Gabriel Choukroun, Laurence Dubel, Maria Lorenzo, Sarah Harmand, Victorio Menoyo Calonge
doi : 10.1093/ckj/sfac245
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 501–511,
Limited real-world data are available in Europe, especially France, regarding the therapeutic management of anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD).
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort
Kaitlin J Mayne, Jennifer S Lees, Elaine Rutherford, Peter C Thomson, Jamie P Traynor, Vishal Dey, Ninian N Lang, Patrick B Mark
doi : 10.1093/ckj/sfac248
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 512–520
Lymphocyte ratios reflect inflammation and have been associated with adverse outcomes in a range of diseases. We sought to determine any association between neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) and mortality in a haemodialysis cohort, including a coronavirus disease 2019 (COVID-19) infection subpopulation.
Association analysis of 10 candidate genes causing Mendelian calcium nephrolithiasis in the INCIPE study: a South European general population cohort
Gloria Santoro, Gianmarco Lombardi, Stefano Andreola, Gian Luca Salvagno, Mirko Treccani, Elena Locatelli, Pietro Manuel Ferraro, Giuseppe Lippi, Giovanni Malerba, Giovanni Gambaro
doi : 10.1093/ckj/sfac225
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 521–527
Idiopathic calcium nephrolithiasis (ICN) is a common condition with a complex phenotype influenced by both environmental and genetic factors. In our study we investigated the association of allelic variants with the history of nephrolithiasis.
Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy
Pim Bouwmans, A Lianne Messchendorp, Céline Imhof, Jan-Stephan F Sanders, Luuk B Hilbrands, Marlies E J Reinders, Priya Vart, Frederike J Bemelman, Alferso C Abrahams, René M A van den Dorpel, Marc A G J Ten Dam, Aiko P J de Vries, Theo Rispens, Maurice Steenhuis, Ron T Gansevoort, Marc H Hemmelder, the RECOVAC Collaborators
doi : 10.1093/ckj/sfac249
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 528–540
Patients with chronic kidney disease (CKD) or kidney replacement therapy demonstrate lower antibody levels after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination compared with healthy controls.
Lung ultrasonography performed by nephrologist: COVID-19 as an opportunity to reveal ultrasound's full potential and usefulness in the dialysis room
Federica N Vigotti, Carlo Di Benedetto, Fabrizio Fop, Simona Bianco, Donatella Bilucaglia, Giulio Cesano
doi : 10.1093/ckj/sfac250
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 541–548
Comparison of a chronic kidney disease predictive model for type 2 diabetes mellitus in Malaysia using Cox regression versus machine learning approach
Ruth Sim, Chun Wie Chong, Navin Kumar Loganadan, Noor Lita Adam, Zanariah Hussein, Shaun Wen Huey Lee
doi : 10.1093/ckj/sfac252
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 549–559
Diabetes is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease. This study aims to develop and validate different risk predictive models for incident CKD and CKD progression in people with type 2 diabetes (T2D).
A deep learning algorithm to quantify AVF stenosis and predict 6-month primary patency: a pilot study
Jae Hyon Park, Jongjin Yoon, Insun Park, Yongsik Sim, Soo Jin Kim, Jong Yun Won, Kichang Han
doi : 10.1093/ckj/sfac254
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 560–570
A deep convolutional neural network (DCNN) model that predicts the degree of arteriovenous fistula (AVF) stenosis and 6-month primary patency (PP) based on AVF shunt sounds was developed, and was compared with various machine learning (ML) models trained on patients’ clinical data.
Drugs associated with incident fragility fractures in kidney transplant recipients
Benjamin Batteux, Alban Nowak, Alice Séjourné, Clémence Penet, Kamel Masmoudi, François Brazier, Solène M Laville, Youssef Bennis, Valérie Gras-Champel, Gabriel Choukroun, Sophie Liabeuf
doi : 10.1093/ckj/sfac265
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 571–584
The risk of fragility fractures is high in kidney transplant recipients, and steroids are reportedly a major cause. Other drugs known to induce fragility fractures have been studied in the general population but not in kidney transplant recipients.
Risks and outcomes of critical limb ischemia in hemodialysis patients: a prospective cohort study
Mu-Yang Hsieh, Shao-Yuan Chuang, Chih-Kuo Lee, Chien-Ming Luo, Chi-Hung Cheng, Min-Tsun Liao, Po-Lin Lin, Ten-Fang Yang, Chih-Cheng Wu
doi : 10.1093/ckj/sfac263
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 585–595
Peripheral arterial disease (PAD) is more common in patients receiving maintenance hemodialysis than in the general population. Critical limb ischemia (CLI), the most severe form of PAD, is associated with high amputation and mortality risk.
Stroke in hemodialysis patients and its association with CHA2DS2-VASC and HAS-BLED scores: a retrospective study
Marc Sab, Dania Chelala, Mabel Aoun, Rabih Azar, Tony Abdel Massih
doi : 10.1093/ckj/sfac260
Clinical Kidney Journal, Volume 16, Issue 3, March 2023, Pages 596–602
In the general population, the CHA2DS2-VASC and the HAS-BLED scores are helpful to predict cerebrovascular events and hemorrhage in patients with atrial fibrillation (AF).
